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Simo˜es-Sousa et al. show that
chromosome missegregation induces
metabolic collapse and apoptosis,
mediated by the p38 stress response
kinase. Inhibiting p38 elevates Hif-1a,
boosts glycolysis, and limits metabolic
collapse, in turn allowing expansion of
aneuploid clones. Adapting to hypoxia
during tumor development may therefore
also permit aneuploidy tolerance.
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Deviating from the normal karyotype dramatically
changes gene dosage, in turn decreasing the robust-
ness of biological networks. Consequently, aneu-
ploidy is poorly tolerated by normal somatic cells
and acts as a barrier to transformation. Paradoxi-
cally, however, karyotype heterogeneity drives tumor
evolution and the emergence of therapeutic drug
resistance. To better understand how cancer cells
tolerate aneuploidy, we focused on the p38 stress
response kinase. We show here that p38-deficient
cells upregulate glycolysis and avoid post-mitotic
apoptosis, leading to the emergence of aneuploid
subclones. We also show that p38 deficiency upre-
gulates the hypoxia-inducible transcription factor
Hif-1a and that inhibiting Hif-1a restores apoptosis
in p38-deficent cells. Because hypoxia and aneu-
ploidy are both barriers to tumor progression, the
ability of Hif-1a to promote cell survival following
chromosome missegregation raises the possibility
that aneuploidy tolerance coevolves with adaptation
to hypoxia.
INTRODUCTION
Aneuploidy, a deviation from the normal karyotype, arises
following chromosome missegregation during mitosis and
meiosis (Holland and Cleveland, 2012; Santaguida and Amon,
2015). This leads to dramatic changes in gene dosage, unbal-
ancing hundreds to thousands of genes, in turn leading to both
chromosome-specific and global changes in transcript levels
(Sheltzer et al., 2012; Torres et al., 2007; Williams et al., 2008).
While post-transcriptional controls can partially buffer the effect
on the proteome (Dephoure et al., 2014; Donnelly and Storchova´,
2014), it is not surprising that gaining or losing an entire chromo-
some has a profound effect on cellular physiology (Gordon et al.,
2012; Oromendia and Amon, 2014). Indeed, aneuploidy appearsCe
This is an open access article undto decrease the robustness of many, if not all, biological pro-
cesses (Beach et al., 2017).
The cellular consequences of aneuploidy include proteotoxic,
lysosomal, and oxidative stress, all contributing to altered meta-
bolism, suppressed proliferation, and reduced fitness (Oromen-
dia et al., 2012; Pfau et al., 2016; Santaguida et al., 2015; Shelt-
zer et al., 2017; Stingele et al., 2012;Williams et al., 2008). In turn,
this has severe organism-level consequences. In humans, aneu-
ploidy is the leading cause of spontaneous abortions, and of the
autosomal trisomies, only Down syndrome individuals (trisomy
21) are able to reach adulthood (Roper and Reeves, 2006). Aneu-
ploidy is also associated with aging. Mice hypomorphic for the
chromosome segregation regulator Bub1b develop aneuploidy
and aging-related phenotypes including cataracts and muscle
wasting (Baker et al., 2004). In humans, BUB1B mutation leads
to mosaic variegated aneuploidy (MVA), a rare disorder charac-
terized by progeroid features and early death (Hanks et al.,
2004).
In some circumstances, aneuploidy can be advantageous.
When yeast cells are placed under strong selective pressure,
aneuploidy can emerge as an adaptive evolutionary response
(Rancati et al., 2008). Aneuploidy can also confer a selective
advantage to human cells cultured under nonstandard condi-
tions (Rutledge et al., 2016). Moreover, genomic instability and
aneuploidy are hallmarks of cancer (Hanahan and Weinberg,
2011). Experimentally inducing aneuploidy can facilitate tumor
evolution in mouse models (Funk et al., 2016), and individuals
with MVA are cancer prone (Hanks et al., 2004). Moreover, in
non-small-cell lung cancer, elevated copy-number heterogene-
ity, an indicator of chromosomal instability, is associated with
shorter relapse-free survival (Jamal-Hanjani et al., 2017). This
paradox (that aneuploidy can inhibit fitness in some contexts
but be advantageous in others) is further illustrated by the ability
of some normal cell types to tolerate aneuploidy. Hepatocytes
frequently become tetraploid and then undergo multipolar divi-
sions, yielding aneuploid daughters (Duncan et al., 2010). More-
over, inactivating the spindle checkpoint gene Mad2 in mouse
skin reveals different responses to aneuploidy; while proliferating
epidermal cells survive, hair follicle stem cells are eliminated via
apoptosis (Foijer et al., 2013). A key question therefore is whatll Reports 25, 749–760, October 16, 2018 ª 2018 The Authors. 749
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
are the context specific mechanisms that allow cells to either
tolerate or be intolerant of aneuploidy?
One factor implicated in aneuploidy tolerance is the p53 tumor
suppressor; for example, mutating p53 in human intestinal stem
cell cultures facilitates the emergence of highly aneuploid orga-
noids (Drost et al., 2015). In addition, p53 is activated following
various mitotic abnormalities (Ditchfield et al., 2003; Lambrus
et al., 2015; Lanni and Jacks, 1998). However, it is not clear
whether this is a direct effect of aneuploidy or an indirect conse-
quence of DNA damage that occurs when chromosomes
become trapped in the cleavage furrow or in micronuclei (Crasta
et al., 2012; Janssen et al., 2011; Li et al., 2010; Thompson and
Compton, 2010). Indeed, a recent study showed that while p53
limits proliferation following errors that lead to structural rear-
rangements, it is not always activated by whole-chromosome
aneuploidies (Soto et al., 2017).
The p38 mitogen-activated protein kinase (MAPK) has also
been implicated in mitotic and post-mitotic responses (Lee
et al., 2010; Takenaka et al., 1998; Vitale et al., 2008), with two
separate studies showing that pharmacological inhibition of
p38 overrides the p53-dependent cell-cycle block following pro-
longed mitosis or chromosome missegregation (Thompson and
Compton, 2010; Uetake and Sluder, 2010). Chromosome insta-
bility also activates MAPK signaling in flies, in this case via JNK
(Dekanty et al., 2012). Because p38 is activated by various
stresses, including proteotoxic and oxidative stress (Cuadrado
and Nebreda, 2010; Cuenda and Rousseau, 2007), these ob-
servations raise the possibility that p38 may also play a role in
aneuploidy tolerance upstream of p53. Here, we explore this
possibility further using pharmacological and CRISPR/Cas9
(clustered regularly interspaced short palindromic repeats/
Cas9) approaches to suppress p38 function, followed by sin-
gle-cell analysis to study mitotic cell fate.
RESULTS
p38 Inhibition Suppresses Apoptosis following
Chromosome Missegregation
To study aneuploidy tolerance, we focused on HCT116 cells, a
near-diploid, chromosomally stable colon cancer cell line with
robust post-mitotic mechanisms that limit proliferation of aneu-
ploid daughters (Lengauer et al., 1997; Thompson andCompton,
2010). To study the role of p53, we employed TP53/ cells
generated by adeno-associated virus (AAV)-enhanced gene tar-
geting (Bunz et al., 2002), and to inhibit p38, we used the ATP-
competitive inhibitor SB203580 (Cuenda et al., 1995). To induce
aneuploidy, we used an inhibitor of the Mps1 spindle checkpoint
kinase, AZ3146, to trigger chromosome missegregation (Hewitt
et al., 2010). Analysis of parental cells exposed to AZ3146
showed a marked increase in cells with sub-2n DNA contents,
indicating apoptosis (Figure S1A). This was ameliorated in
TP53/ cells and by SB203580, consistent with p53 and p38
being required for apoptosis following chromosome missegre-
gation. TP53/ andSB203580-exposed cells also entered addi-
tional cell cycles and accumulated aneuploidies following Mps1
inhibition (Figure S1B).
The AAV-generated HCT116 TP53/ cells have been exten-
sively passaged and, due to their mismatch repair defect, have750 Cell Reports 25, 749–760, October 16, 2018likely undergone extensive genetic drift (Lengauer et al., 1997).
Indeed, introducing p53 transgenes into these cells results in
lethality (D. Jackson, personal communication). Therefore, to
analyze p38 and p53 in more closely matched cells, we gener-
ated TP53/ cells using CRISPR/Cas9-mediated gene editing
and analyzed them at low passage (Figure 1A). Importantly, the
CRISPR-generated TP53/ cells remained near diploid (Fig-
ure S1C), confirming that p53 loss is insufficient to induce aneu-
ploidy, at least in HCT116 cells (Bunz et al., 2002).
To measure cell-cycle timing, apoptosis, and post-mitotic
behavior, we used time-lapse imaging in conjunction with a fluo-
rescent caspase-3/7 reporter (Topham et al., 2015). AZ3146
induced extensive apoptosis in parental cells, and again, this
was ameliorated by p53 loss and SB203580 (Figure 1B). Cell
fate profiling showed that 52% of parental cells underwent
apoptosis following mitosis (Figure 1C), with 36% dying after
the first mitosis and only 37% entering a second mitosis (Fig-
ure S1D). While p53 mutation had a modest effect, reducing
apoptosis to 38%, SB203580 had a more substantial effect,
reducing apoptosis to 20%, with 53% of cells entering a second
mitosis (Figure 1C). Inactivating p53 enhanced the SB203580 ef-
fect (e.g., increasing the number of cells entering a second
mitosis from 53% to 70%) (Figure S1D). Thus, we conclude
that while both p53 and p38 enhance apoptosis following chro-
mosomemissegregation, analysis of more closely matched lines
indicates that inhibition of p38 yields a more penetrant effect.
p38 Is Activated following Induction of Whole-
Chromosome Aneuploidy
Because SB203580 suppresses apoptosis following spindle as-
sembly checkpoint (SAC) override, we asked if the canonical p38
pathway was activated following chromosome missegregation.
However, SAC override induces a variety of mitotic abnormal-
ities, some of which can lead to DNA damage (Crasta et al.,
2012; Janssen et al., 2011). Indeed, inhibition of DNA-PK, which
is required for non-homologous end joining (NHEJ), further
suppressed apoptosis in AZ3146-treated cells exposed to
SB203580 (Figure S1A). By contrast, ATM and ATR inhibitors
had little effect (data not shown). Interestingly, NHEJ is required
for chromosome repair following chromothripsis, localized
genomic rearrangements that follow incorporation of missegre-
gated chromosomes into micronuclei (Ly et al., 2017). Therefore,
to minimize DNA damage, we employed GSK923295, which in-
hibits the Cenp-E kinesin, allowing most chromosomes to align
at the cell equator but blocking a small number near the spindle
poles (Wood et al., 2010). Upon triggering anaphase via Mps1 in-
hibition, these polar chromosomes are missegregated without
being trapped in the spindle midzone, which could otherwise
lead to DNA damage, chromosome breakage, and structural
aneuploidy (Bennett et al., 2015; Soto et al., 2017). To evaluate
this approach in HCT116, cells harboring a GFP-tagged histone
were exposed to GSK923295 and analyzed by time-lapsemicro-
scopy. Mitotic cells with polar chromosomes were readily
apparent, and addition of AZ3146 triggered their missegregation
without chromosome trapping (Figure 2A).
Having confirmed that sequential inhibition of Cenp-E and
Mps1 induces aneuploidy in HCT116 cells, mitotic cells exposed
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Figure 1. SB203580 Suppresses Apoptosis
following Chromosome Missegregation
(A) Immunoblots showing p53 loss following
CRISPR/Cas9-mediated mutation of TP53.
(B and C) Line graphs (B) and cell fate profiles (C)
showing that p53 mutation and exposure to the
p38 inhibitor SB203580 suppress apoptosis
induced by the Mps1 inhibitor AZ3146. In (B),
values show mean ± SD from three technical
replicates and are representative of three inde-
pendent experiments. In (C), numbers in bars
indicate the percentage of cells exhibiting the fate
indicated by bar color.
See also Figure S1.in AZ3146, harvested at various time points, and then analyzed
by immunoblotting to interrogate the p38 pathway. Note that
p38 is phosphorylated by upstream kinases MKK3/6, in turn
leading to phosphorylation of MK2 and Hsp27 (Figures 2B and
S2A). 2 hr after driving GSK923295-arrested cells into anaphase,
levels of phospho-p38 notably increased, as did phosphorylated
MKK3/6, MK2, and Hsp27 (Figure 2C). p53 and p21 also
increased over the 6-hr time course, although this increase
was slightly delayed compared to p38 activation. However, the
parallel ERK and JNK pathways did not show signs of activation.
Importantly, under these conditions, DNA damage was not
apparent, and inhibitors targeting ATM, ATR, and DNA-PK did
not suppress p38 activation (Figures S2B and S2C). While these
observations support the notion that p38 is activated upon aneu-
ploidy induction, a caveat arises, because a mitotic delay can be
sufficient to induce a p38-dependent response (Uetake and
Sluder, 2010). To address this, we released cells from a mitotic
block with and without the Mps1 inhibitor. Importantly, only in
the presence of the AZ3146 did we observe elevated p38 phos-
phorylation (Figures S2C and S2D). Moreover, driving cells from
the mitotic block with an Aurora B inhibitor, thereby inducing
tetraploidy rather than aneuploidy, failed to activate p38
(Figure S2C).Cell Rp38a Promotes Apoptosis following
Chromosome Missegregation
To validate our observations derived from
pharmacological inhibition of p38, we
used CRISPR/Cas9 to mutate MAPK14,
which encodes p38a, the isoform ex-
pressed in most cell types (Cuenda and
Rousseau, 2007). Using two different sin-
gle guide RNAs (sgRNAs) we generated
two independent clones devoid of p38a
(Figures 3A and S3A). These lines lacked
p38 signaling, as evidenced by lack of
MK2 phosphorylation following exposure
to hydrogen peroxide (Figure 3B). Time-
lapse imaging showed that AZ3146-
induced apoptosis was suppressed to
near basal levels in both p38a null clones
(Figure 3C and S3B). Cell fate profiling
confirmed this. Within 48 hr, 59% of
parental cells underwent post-mitoticdeath; by contrast, only 10% of the p38a null cells died (Fig-
ure 3D). Also, whereas only 18% of parental cells entered a sec-
ond mitosis, 50% of the p38a null cells did so (Figure S3C). The
independent p38a null clone was also resistant; only 4% of cells
died, while 82% entered a second mitosis (Figures S3B and
S3C). Other cell-cycle parameters, including mitotic duration
and time between successive mitoses, appeared unaffected
by p38amutation (Figure S3D). To test whether apoptosis avoid-
ance led to longer-term survival, cells exposed to AZ3146 for 24,
48, and 72 hr were allowed to grow out into colonies. Notably, the
p38a null clone yielded more colonies across the entire time
course (Figure 3E). Thus, we conclude that p38a promotes
post-mitotic apoptosis following chromosome missegregation.
Note that some p38a null cells failed cell division in the presence
of AZ3146 due to abscission failure, yielding tetraploid cells; we
discuss this issue below. To ascribe the p38a-dependent effect
to an aneuploidy response, as opposed to DNA damage, we
exposed p38a null to GSK923295 and AZ3146 as described
above (Figure 2). However, to avoid complications associated
with a mitotic delay, we exposed the cells to both inhibitors
simultaneously (Soto et al., 2017). Time-lapse imaging showed
that 63% of cells entered anaphase with unaligned chromo-




































Figure 2. p38 Is Activated following Induction of Whole-Chromo-
some Aneuploidy
(A) Time-lapse image sequences of HCT116 cells expressing GFP-H2B
exposed to the Cenp-E inhibitor GSK923295 then AZ3146 to induce mis-
segregation of polar chromosomes. Numbers represent minutes after imaging
started; AZ3146 was added at t = 9 min. Scale bar, 10 mm.
(B) Canonical p38 MAPK pathway showing upstream regulators and down-
stream targets.
(C) Immunoblots of post-mitotic cells harvested at the time points indicated
following exposure to GSK923295 then AZ3146.
See also Figure S2.(Note that previously, post-mitotic responses only manifested
when mitosis was delayed beyond 90 min; Uetake and Sluder,
2010.) Under these conditions, p38a loss also suppressed
apoptosis and enhanced colony formation (Figures S3F–S3H),




As alluded above, p53 accumulation was attenuated in p38a
null cells (Figure 3B). To measure p53 accumulation more
directly, we integrated GFP into the endogenous TP53 using
CRISPR/Cas9. Immunoblotting confirmed that all the detect-
able p53 was expressed as a GFP fusion, suggesting that
both TP53 alleles had been modified (Figure 4A). Importantly,
like untagged p53, the GFP fusion also accumulated upon Nut-
lin-3-mediated inhibition of Mdm2. Moreover, fluorescence
microscopy and time-lapse imaging demonstrated nuclear
accumulation of GFP in response to both Nutlin-3 and
AZ3146 (Figures 4B and 4C). To determine functionality of the
GFP-p53 fusion, we analyzed proliferation in the presence
and absence of Nutlin-3. As expected, Nutlin-3 inhibited prolif-752 Cell Reports 25, 749–760, October 16, 2018eration of parental cells, but not p53 null cells (Figure S4A).
Importantly, Nutlin-3 suppressed proliferation of GFP-p53 cells,
demonstrating functionality of the fusion. Nutlin-3 also induced
p21 in GFP-p53 cells, further supporting this conclusion (Fig-
ure 4A). Having validated the GFP-p53 biosensor, we mutated
MAPK14 with CRISPR/Cas9 (Figure S4B) and used time-lapse
imaging to measure GFP fluorescence upon exposure to
AZ3146. Over 72 hr, GFP increased in p38a-proficient cells
but was attenuated in p38a null cells (Figure 4D). To confirm
this reflected the loss of p38a, we restored its function by stably
transfecting a p38a cDNA into GFP-p53 MAPK14/ cells (Fig-
ure S4B). Importantly, this restored accumulation of GFP-p53
(Figure 4D). Thus, we conclude that p38a does indeed
contribute to p53 accumulation following chromosome misse-
gregation. Whether this reflects a direct effect is unclear. Note
also that the p38a cDNA restored post-mitotic apoptosis in
AZ3146-treated cells; whereas only 18% of the p38a null cells
died, 62% did so in the p38a rescue line (Figure 4E), confirming
that reduced post-mitotic apoptosis in MAPK14/ cells is
indeed due to loss of p38a function.
p38a Promotes Post-mitotic Apoptosis by Suppressing
Hif-1a
To dissect how p38a promotes post-mitotic apoptosis, we
considered several approaches. Because proteomic analyses
of aneuploid cells highlight alterations in oxidative stress and
metabolism (Dephoure et al., 2014; Donnelly and Storchova´,
2014), we turned to real-time measurement of metabolic param-
eters using Seahorse XF technology. Parental and p38a null cells
were treated with AZ3146 for 24 hr, and then the extracellular
acidification rate (ECAR) and oxygen consumption rate (OCR)
were analyzed. Notably, exposing parental cells to AZ3146 sup-
pressed both ECAR and OCR, indicating suppressed glycolysis
andmitochondrial respiration, respectively (Figure 5A; Table S1).
More strikingly, both parameters were elevated in p38a null cells,
and while exposure to AZ3146 still suppressed both ECAR and
OCR, they weremaintained at values observed in untreated con-
trols. Based on this, we speculated that by enhancing metabolic
parameters, p38a mutation allows cells to buffer the conse-
quences of chromosome missegregation, thus enhancing
survival.
To test this notion, we turned to Hif-1, a heterodimeric tran-
scription factor and master regulator of glycolysis (Porporato
et al., 2011). Notably, Hif-1a was elevated in both p38a null
clones (Figures 5B and S5A). Moreover, it was elevated in
GFP-p53 MAPK14/ cells, and restoring p38a suppressed
Hif-1a to basal levels (Figure S4B). To test whether elevated
Hif-1a caused apoptosis suppression in p38a nulls, we
repressed Hif-1a using RNAi (Figure 5C). Hif-1a depleted cells
were then analyzed by time-lapse microscopy, with Tao1 small
interfering RNAs (siRNAs) serving as a negative control. Consis-
tent with observations above, the extensive apoptosis induced
by AZ3146 in controls was suppressed by p38a mutation (Fig-
ure 5D). Importantly, Hif-1a RNAi restored apoptosis in p38a
null cells. This was confirmed by cell fate profiling; while Hif-1a
RNAi had only a marginal effect on parental cells, increasing
post-mitotic apoptosis from 64% to 72%, it had a dramatic ef-


































































































-/- Figure 3. p38a Promotes Apoptosis
following Chromosome Missegregation
(A) Immunoblot showing p38a loss following
CRISPR/Cas9-mediated mutation of MAPK14.
(B) Immunoblots of parental and p38a null cells
exposed to H2O2 for 30 min (left) or AZ3146 for
24 hr (right). Arrow highlights a background band.
(C–E) Line graphs (C), cell fate profiles (D), and
colony formation assay (E) showing suppression of
AZ3146-induced apoptosis in p38a null cells. In
(C), values show mean ± SD from three technical
replicates and are representative of three inde-
pendent experiments. Quantitation in (E) shows
the mean ± SD derived from two independent
experiments.
See also Figure S3.(Figure 5E). Analysis of the second MAPK14/ clone yielded
a similar result, with Hif-1a RNAi restoring AZ3146-induced
apoptosis from 26% to 54% (Figure S5B). Thus, we conclude
that suppressed post-mitotic apoptosis in p38a null cells can
be explained by elevated Hif-1a. Based on the large body of
evidence demonstrating that Hif-1a drives glycolytic path-
ways (Kim and Dang, 2006; Porporato et al., 2011; Semenza,
2011), one possible explanation for these observations is that




Our observations demonstrate that p38a
promotes apoptosis following chromo-
some missegregation (Figures 3, 4, and 5)
and that p38a’s role enhances longer-
term survival following spindle checkpoint
override (Figure 3E). To determinewhether
the p38a-deficient survivors are indeed
aneuploid and that they retained deviant
karyotypes following clonal expansion,
parental and p38a null cells were exposed
to AZ3146 for 24 hr, expanded for a further
25 days, and then analyzed indepen-
dently using two orthogonal approaches,
namely traditional chromosome spreads
(Tighe et al., 2004) and single-cell whole-
genome sequencing (scWGS) (Bakker
et al., 2016; van den Bos et al., 2016).
As expected, untreated parental cells
had near-diploid chromosome counts,
with 67% possessing the modal chromo-
some number (Figure S6A). By contrast,
chromosome numbers in AZ3146-treated
cultures deviated considerably, ranging
from40 to92. Interestingly,whileuntreated
p38a null cells were largely near diploid,
only 19% had the modal chromosome
count, suggesting that p38a null cellsaccumulate aneuploidies without experimentally inducing chro-
mosome missegregation.
To analyze the populations by scWGS, G1 cells were isolated
by flow sorting and then subjected to next-generation
sequencing. In untreated parental cells, we observed clonal
copy-number gains affecting chromosomes 8, 10, 16, and 17
(Figure S6B). Note that these gains reflect translocations as pre-
viously reported for HCT116 (Abdel-Rahman et al., 2001) and


















































































Figure 4. p38a Promotes p53 Stabilization
following Chromosome Missegregation
(A) Immunoblot showing expression of a GFP-p53
fusion protein following CRISPR/Cas9-mediated
targeting of TP53.
(B) Immunofluorescence images and quantitation
showing nuclear GFP-p53 following exposure to
Nutlin-3 and AZ3146. Scale bar, 10 mm. Box and
whisker plot shows median, interquartile range,
and full range from 431 cells per condition from
one biological replicate. ****p < 0.0001.
(C) Line graph showing accumulation of green
fluorescence in GFP-p53 cells following exposure
to Nutlin-3 and AZ3146.
(D) Line graphs showing reduced accumulation of
green fluorescence in p38a null cells exposed to
AZ3146 and restoration following p38a rescue.
In (C) and (D) values show mean ± SD from three
technical replicates and is representative of three
independent experiments. (E) Cell fate profiles of
GFP-p53 cells showing suppression of AZ3146-
induced apoptosis in p38a null cells and restora-
tion in p38a rescue cells.
See also Figure S4.(M-FISH) analysis (see below). Beyond this baseline, out of 23
untreated p38a null cells, three had a trisomy affecting either
chromosome 2 or 13; and out of 22 AZ3146-treated cells, one
had a highly deviant karyotype trisomic for six chromosomes
and monosomic for another five (Figure 6). During the flow sort-
ing, we observed a substantial number of AZ3146-treated p38a
null cells with 4N DNA contents (not shown), consistent with
abscission failure highlighted by the cell fate profiling (Figure 3D).
scWGS confirmed that these cells were near tetraploid but with a
number of chromosome losses (Figure S6B). Nevertheless,
scWGS analysis of the near-diploid cells supports the notion
that p38a null cells are more likely to accumulate aneuploidies.
Pharmacological Inhibition of p38 Facilitates Expansion
of Aneuploid Clones
While the scWGS identified aneuploidies in the p38a null popu-
lation, we noted three limitations with this experiment. First,754 Cell Reports 25, 749–760, October 16, 2018untreated p38a nulls already showed
signs of aneuploidy. Second, if aneu-
ploidy has a fitness cost, it may be under-
represented when analyzing populations
due to outcompeting diploid survivors.
Finally, by inducing tetraploidy, p38amu-
tation might provide AZ3146-treated
cells with an alternative survival mecha-
nism not related to aneuploidy tolerance
per se. To address these issues, we re-
turned to pharmacological inhibition of
p38 in parental cells. Note that in contrast
to p38a mutation, SB203580 does not
induce cell division failure in Mps1-in-
hibited cells (Figure 1). Cells were treated
with AZ3146 for 48 hr and allowed to
recover for a further 48 hr, and then singlecells were expanded in the presence or absence of SB203580
before independent analysis using two orthogonal approaches:
chromosome counting and M-FISH (Figure 7A). Chromosome
counts showed that substantially more SB203580-treated cells
deviated from the mode of 45 (Figure 7B). Indeed, the average
deviation in controls was 0.63 compared to 1.11 in the
SB203580-treated arm (Figure 7C). M-FISH confirmed that
SB203580-treated clones were indeed aneuploid, with clone
5A trisomic for chromosomes 2, 9, and 19 and clone 5C trisomic
for chromosome 18 (Figure 7D). By contrast, control clones
exhibited the typical HCT116 karyotype (Figure S7). Interest-
ingly, while all cells in 5A were trisomic for chromosome 19,
chromosomes 2 and 9 were more heterogeneous, indicative
of chromosome instability (Figure 7E). Nevertheless, we
conclude that pharmacological inhibition of p38 following chro-









































































































Figure 5. p38a Promotes Post-mitotic
Apoptosis by Suppressing Hif-1a
(A) Line graphs showing the extracellular acidifi-
cation rate (ECAR) and oxygen consumption rate
(OCR) in parental and p38a null cells after expo-
sure to AZ3146 for 24 hr. Values show mean ±
SEM from three independent experiments (see
Table S1), normalized to the maximal value
observed in untreated parental cells.
(B) Immunoblot showing elevated Hif-1a in p38a
null cells.
(C) Immunoblot showing RNAi-mediated repres-
sion of Hif-1a; note also elevated Hif-1a in control
p38a null cells.
(D and E) Line graphs (D) and fate profiles (E)
showing restorationofAZ3146-mediatedapoptosis
in p38a null cells following siHif-1a. In (D), values
show mean ± SD from two technical replicates
and is representative of three independent experi-
ments.
See also Figure S5.DISCUSSION
As cancer cells acquire the characteristics that distinguish them
from normal cells, aneuploidy emerges as a common feature
(Sansregret et al., 2018). However, some cancers retain near-
diploid karyotypes because they retain segregation fidelity
and/or because they do not tolerate aneuploid genomes. This
is illustrated by colorectal cancers, which broadly fall into two
classes: those that exhibit microsatellite instability (MIN; 20%)
and remain near diploid and those that are microsatellite stable
but display chromosome instability (CIN; 80%) and acquire high-
ly divergent karyotypes (Lengauer et al., 1997; Lo´pez-Garcı´a
et al., 2017). Due to this dichotomy,MIN cells are tractablemodel
systems for studying both segregation fidelity and aneuploidyCell Rtolerance, and indeed, several pathways
that contribute to CIN have now been
identified (Ertych et al., 2014; Stolz
et al., 2010). More recently, the ability of
MIN cells tomount robust post-mitotic re-
sponses following experimental induction
of chromosomemissegregation has been
exploited to shed light on aneuploidy
tolerance. For example, inhibiting BCL9L
in HCT116 cells suppresses apoptosis
following spindle checkpoint override,
permitting survival of aneuploid cells (Lo´-
pez-Garcı´a et al., 2017). Interestingly, this
is only partially explained by an effect on
p53; BCL9L mutation prevents caspase-
2-mediated cleavage of BID, thus sup-
pressing apoptosis regardless of p53
status. Similarly, a genome-wide screen
for Taxol sensitizers in another MIN line,
RKO, identified a MYC-dependent, p53-
independent apoptosis module that elim-
inates cells following an aberrant mitosis
(Topham et al., 2015). Here, we identifyan additional mechanism, one dependent on the p38 stress
response kinase, that when suppressed allows HCT116 cells
to avoid apoptosis following chromosome missegregation, in
turn leading to the emergence of aneuploid clones. While p38
can modulate apoptosis pathways directly (Cuadrado and Ne-
breda, 2010), one possible explanation for our observations is
that in this context, p38 suppresses aneuploidy tolerance by
suppressing Hif-1-dependent glycolytic networks. An important
next step will be to explore these concepts in additional cell lines
and preclinical models.
In addition to chromosome instability, another hallmark of can-
cer cells is altered metabolism, in particular shifting ATP gener-
ation from oxidative phosphorylation to increased glycolysis,












































Figure 6. p38a-Deficient Cells Accumulate Whole-Chromosome
Aneuploidies
Genome-wide chromosome copy-number profile of parental and p38a null
cells as determined by single-cell sequencing, with colored boxes highlighting
whole-chromosome aneuploidies not observed in parental cells. See also
Figure S6.


























































No Mps1i, p38 washout 









Figure 7. Pharmacological Inhibition of p38 Facilitates Expansion of
Aneuploid Clones
(A) Experimental design generating clones in the presence or absence of the
p38 inhibitor SB203580 following exposure to AZ3146.
(B) Chromosome counts showing the deviation from the modal number of 45,
analyzing 25 spreads from at least 10 independent clones for each condition.
(C) Box and whisker plot showing the average deviation from 45 for clones
exposed to AZ3146 ± SB203580. **p < 0.01.
(D) RepresentativeM-FISH karyotypes from clones 5A and 5C, both generated
in the continuous presence of SB203580. Boxes highlight whole-chromosome
aneuploidies.
(E) Quantitation of M-FISH karyotypes showing recurrent trisomies for chro-
mosome 2, 9, and 19 (clone 5A) and chromosome 18 (clone 5C).
See also Figure S7.is present, a phenomenon known as the Warburg effect (Liberti
and Locasale, 2016; Vander Heiden and DeBerardinis, 2017).
Although less efficient, this shift offers cancer cells several ad-
vantages, including enhanced proliferation and biosynthesis,
the ability to buffer reactive oxygen species (ROS), and, by allow-
ing ATP production in the absence of oxygen, adaptation to hyp-
oxia (Cairns et al., 2011). Indeed, because tumor growth leads to
hypoxic microenvironments, this metabolic shift facilitates can-
cer cell survival in advance of neovascularization. A key driver
of the shift to glycolysis is Hif-1a, which, in response to hypoxia,
amplifies expression of genes encoding glucose transporters
and glycolytic enzymes. Because enhanced glucose uptake
and increased lactate production are also characteristics of
non-transformed aneuploid cells, Amon and colleagues have
explicitly noted the similarity between the Warburg effect and
the metabolic changes caused by aneuploidy (Siegel and
Amon, 2012; Williams et al., 2008). Moreover, analysis of copy-
number variations across 15 tumor types revealed that glycol-756 Cell Reports 25, 749–760, October 16, 2018ysis-associated genes are frequently amplified in tumors with
high genomic instability, indicating that metabolic stress drives
the evolution of highly aberrant genomes (Graham et al., 2017).
Our observations also suggest a reciprocal relationship whereby
not only does aneuploidy induce metabolic changes but also the
Warburg effect perhaps facilitates aneuploidy tolerance. We
show that glycolysis is suppressed immediately following chro-
mosome missegregation but that when p38a is mutated, Hif-
1a increases, glycolysis is enhanced, and post-mitotic apoptosis
is suppressed. A causal link between elevated Hif-1a and post-
mitotic survival is evidenced by the restoration of apoptosis upon
RNAi-mediated repression of Hif-1a. One possibility therefore is
that p38a suppresses aneuploidy tolerance by limiting the War-
burg effect. Testing this notion will require analyzing other meta-
bolic parameters, including glucose uptake, lactate production,
and glycolytic flux, in the context of p38a signaling and chromo-
some missegregation.
p38 is activated in response to various cellular stresses, in turn
modulating multiple downstream pathways, the net effect of
which is highly context dependent, explaining p38Hs role in
various pathologies, including inflammation, cancer immune re-
sponses, heart disease, and neurodegeneration (Cuenda and
Rousseau, 2007). We cannot therefore rule out the possibility
that p38a promotes post-mitotic apoptosis via canonical stress
response pathways, for example directly via p53 or the
apoptosis machinery (Bulavin et al., 1999). Note however, that
while p53 stabilization is attenuated in p38a mutant cells, this
may also be an indirect effect of elevated Hif-1a. Also, because
p38 inhibition suppresses post-mitotic apoptosis more potently
than p53 mutation, the effect of p38 is unlikely to be exclusively
via p53. Moreover, the notion that p38 suppresses Hif-1 is not
unprecedented; it was recently shown that in C. elegans, under
normoxic conditions, the p38 MAPK ortholog PMK-1 activates
the EGL-9 prolyl hydroxylase, which triggers Hif-1 turnover
(Park and Rongo, 2016). Thus, loss-of-function mutations in
PMK-1, or the upstreammitogen-activated protein kinase kinase
(MAPKK) ortholog SEK-1, mimic the effects of hypoxia, including
nuclear accumulation of Hif-1 and upregulation of target genes.
Thus, the de-repression of Hif-1awe observe following mutation
of p38a in HCT116 cancer cells appears to reflect an evolu-
tionarily conserved mechanism relevant to normal physiology.
An important next step will be delineating how p38 modulates
Hif-1 function in human cells.
Our cell fate profiling revealed an unexpected finding: a sub-
stantial number of p38a null cells generated by CRISPR/Cas9-
mediated gene editing underwent abscission failure when
exposed to the Mps1 inhibitor. While p38 has been implicated
in chromosome segregation and cytokinesis (Tormos et al.,
2017), the abscission failure appears to be a synthetic effect,
as it was not observed in untreated p38a mutants or AZ3146-
treated control cells. Importantly, the abscission failure was
not reverted by expression of a p38a cDNA, suggesting that it
may be the result of an off-target CRISPR/Cas9 phenomenon.
This seems unlikely, as it was also observed in a second p38a
null clone, albeit to a lesser extent, despite this mutation being
generated using an independent sgRNA targeting MAPK14.
One possibility that we are currently exploring is that this reflects
an adaptive response to loss of p38a function during the clonal
expansion following the CRISPR/Cas9 process. Another possi-
bility is that aneuploidy induced by loss of p38 may predispose
cells to cytokinesis failure, a phenomenon described in trisomic
DLD-1 cells (Nicholson et al., 2015). Nevertheless, it raises thepossibility that post-mitotic survival of p38a null cells is a conse-
quence of avoiding aneuploidy by becoming tetraploid. Indeed,
by buffering the damaging effects of chromosome missegrega-
tion, tetraploidy can produce viable albeit highly abnormal prog-
eny (Holland and Cleveland, 2012; Storchova and Kuffer, 2008).
Consistent with this notion, an siRNA library screen for genes
that enhanced HCT116 cell survival upon exposure to AZ3146
yielded Aurora B, a cytokinesis regulator, as the top hit (data
not shown). Note also that genome doubling is a frequent evolu-
tionary stepping stone during tumorigenesis (Dewhurst et al.,
2014; Galipeau et al., 1996). However, several reasons suggest
that tetraploidy is insufficient to account for the enhanced sur-
vival of p38a null cells. First, as alluded above, whenwe analyzed
an independent p38a null clone, only 12% of cells failed abscis-
sion after the first mitosis, yet 96% of the cells survived. Second,
when we restored p38a or repressed Hif1a, cells that failed
abscission now died. Third, upon pharmacological inhibition of
p38, we did not observe abscission failure, yet cells survived
and aneuploid clones emerged. Finally, p38a null cells acquired
aneuploidies even when not being exposed to the Mps1
inhibitor.
To conclude, our observations have a provocative corollary
relating to tumor evolution and the aneuploidy paradox. Hypox-
ia and the fitness cost incurred by aneuploid cells are barriers to
tumor progression. However, the ability of elevated Hif-1a to
permit cell survival following chromosome missegregation rai-
ses the possibility that adapting to hypoxic conditions during
the early avascular phase of tumor development may also
permit aneuploidy tolerance. An important next step will be to
test these concepts in models that recapitulate the tumor
microenvironment.STAR+METHODS
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D-(+)-Glucose Sigma Aldrich Cat# G8644
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Hoechst 33258 Sigma Aldrich Cat# B1155
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Sodium Pyruvate Sigma Aldrich Cat# S8636
Tetracycline hydrochloride Sigma Aldrich Cat# T7660
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FISH Probes 24XCyte, Human mFISH Probe Kit Zeiss MetaSystems Cat# D-0125-060-DI
Genomic DNA Extraction Kit Invitrogen Cat# 1851095
QIAprep Spin Miniprep Kit QIAGEN Cat# 27106
REDTaq DNA Polymerase Sigma Aldrich Cat# D4309
RNeasy Plus Mini Kit QIAGEN Cat# 74134
Seahorse XF Cell Mito Stress Test Kit Agilent Technologies Cat# 103015-100
Seahorse XF Glycolysis Stress Test Kit Agilent Technologies Cat# 103020-100
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Archive (ENA)
Accession# PRJEB27319
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Collection
Cat# HCT-116; RRID: CVCL_0291
Human: HCT116 TP53/ (male) A gift from Bert Vogelstein
(Bunz et al., 2002)
N/A
Human: HCT116 Flp-InTM T-RExTM (male) This study N/A




sgRNA targeting TP53: 50 AAT GTT TCC TGA CTC AGA GG 30 Horizon Discovery N/A
sgRNAs targeting MAPK14: 50 GAC AGG TTC TGG TAA CGC
TC 30; 50 CCA TAG GCG CCA GAG CCC AC 30
Horizon Discovery N/A
siRNA ON-TARGETplus SMARTpool targeting HIF-1a: 50 GAA
CAA AUA CAU GGG AUU A 30; 50 AGA AUG AAG UGU ACC
CUA A 30; 50 GAU GGA AGC ACU AGA CAA A 30; 50 CAA GUA
GCC UCU UUG ACAA 30
Dharmacon/ Horizon Discovery Cat# L-004018-00-0005
siRNA targeting Tao1: 50 GUA AUA UGG UCC UUU CUA A 30 (Westhorpe et al., 2010) N/A
Nested-PCR: TP53 forward primers: F1 - 50 CAG GAA GGG
AGT TGG GAA TAG 30; F2 – 50 GAA GTG CAT GGC TGG
TGAG GG 30
This study N/A
Nested-PCR: TP53 reverse primers: R1 – 50 GGA CCT GGG
TCT TCA GTG AAC 30; R2 – 50 GAG CAG TCA GAG GAC
CAG GTC 30
This study N/A
RT-PCR p38a-XhoI forward primer: CAC CTC GAG TCT CAG
GAG AGG CCC ACG TTC
This study N/A
RT-PCR p38a-NotI reverse primer: CAC GCG GCC GCT CAG
GAC TCC ATC TCT TCT TG
This study N/A
Recombinant DNA
cDNA: MAPK14, transcript variant 2 (p38 alpha) This study Accession# NM_139012
pBluescript II SK- vector Agilent genomics Cat# 212206
pBluescript/GFP/P53-800 This study N/A
pcDNA5/FRT/TO Invitrogen Cat# V652020
pcDNA5/FRT/TO/GFP-H2B This study
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pcDNA5/FRT/TO-p38a This study N/A
pD1301-AD:153663 TP53_48277 Horizon Discovery N/A
p38a sgRNA plasmid (clone 1): pD1301-AD:155747
MAPK14_25032
Horizon Discovery N/A
p38a sgRNA plasmid (clone 2): pD1301-AD:155748
MAPK14_25033
Horizon Discovery N/A
pOG44 Flp-Recombinase Invitrogen Cat# V600520
Software and Algorithms
AneuFinder (Bakker et al., 2016) https://www.rdocumentation.org/
packages/AneuFinder/versions/1.0.3
Bowtie2 (Langmead and Salzberg, 2012) http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml; RRID:
SCR_016368
Bravo Automated Liquid Handling Platform Agilent Technologies N/A
CellASIC ONIX Merck Millipore CAX2-S0000
ChemiDoc Touch Imaging System BioRad 1708370
FastQ screen Babraham Institute http://www.internationalgenome.org/
category/fastq/; RRID: SCR_000141
GelCount Oxford Optronix N/A
Illumina NextSeq 450 System Illumina RRID: SCR_014983
Illustrator CC 2018 Adobe Systems https://www.adobe.com/uk/products/
illustrator.html; RRID: SCR_010279
IncucyteZOOM Essen Bioscience GUI = 2016A







Prism 7 GraphPad https://www.graphpad.com/; RRID:
SCR_002798
Seahorse Wave Agilent Technologies RRID: SCR_014526
VisionWorks LS UVP N/A
Other
6-well plates Corning Cat# 353046
24-well plates Corning Cat# 353047
96-well black mclear plates Greiner Bio-One Cat# 655087
96-well clear plates Corning Cat# 353072
DharmaFECT 1 Dharmacon/ Horizon Discovery Cat# T-2001-03
Dulbecco’s Modified Eagle Medium (DMEM) Life Technologies Cat# 41966052
EZ-Chemiluminescence Detection Kit for HRP Geneflow Limited Cat# KI-0172
Fetal Bovine Serum Heat Inactivated Life Technologies Cat# F9665
FluoroBrite DMEM media Life Technologies Cat# A1896701
Immobilon-P PVDF Membrane Merck Millipore Cat# IPVH00010
IncuCyte Caspase 3/7 Green Apoptosis Reagent Essen BioScience Cat# 4440
Lipofectamine Plus Invitrogen Cat# 18324012
Lipofectamine 2000 Invitrogen Cat# 11668019
Luminata Forte Western HRP Substrate Merck Millipore Cat# WBLUF0100
Opti-MEM Life Technologies Cat# 11058021
Quick Start Bradford 1x Dye Reagent Bio-Rad Laboratories Cat# 5000205
Seahorse XF Base Medium Agilent Technologies Cat# 102353-100
Seahorse XFe96 Fluxpak Mini Agilent Technologies Cat# 102601-100
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S. Taylor (stephen.taylor@manchester.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Cell Lines
The human, male colon carcinoma cell line HCT116 was obtained from the American Type Culture Collection (ATCC). HCT116 Flp-
InTM T-RExTM derivatives were generated using the Flp-InTM T-RExTM System (Invitrogen) according to manufacturer instructions.
HCT116 TP53/ cells generated by rAAV-mediated homologous recombination were provided by Bert Vogelstein (Bunz et al.,
2002). To create the HCT116 Flp-InTM T-RExTM GFP-H2B cell line, an open reading frame encoding histone H2B was generated
by RT-PCR amplification (Invitrogen) of mRNA prepared from HCT116 cells and cloned as a GFP-tagged fusion into a pcDNA5/
FRT/TO-based expression vector (Invitrogen). This plasmid was transfected into the HCT116 Flp-InTM T-RExTM cell line using Lip-
ofectamine Plus (Invitrogen), following manufacturer’s instructions. Cell lines were cultured in DMEM plus 10% fetal calf serum
(Life Technologies), 100 U/ml penicillin, 100 U/ml streptomycin and 2 mM glutamine (all from Sigma), then maintained at 37C in a
humidified 5% CO2 atmosphere. All cell lines were authenticated by the Molecular Biology Core Facility at the CRUK Manchester
Institute using Promega Powerplex 21 System and periodically tested for mycoplasma.
METHOD DETAILS
Materials and plasmids
AZ3146 (Hewitt et al., 2010), SB203580 (Tocris Bioscience), DNA-PK inhibitor II (Calbiochem), GSK923295 (Bennett et al., 2015),
Nutlin-3 and nocodazole were dissolved in DMSO, stored at20C - except for Nutlin-3 that was stored at80C - and used at final
concentrations of 2 mM, 10 mM, 10 mM, 100 nM, 10 mMand 0.66 ng/ml respectively unless indicated otherwise. Hygromycin B (Sigma)
and hydrogen peroxide (Sigma) were stored at 4C and used at the final concentrations of 400 mg/ml and 500 mM, respectively.
CRISPR/Cas9-mediated mutagenesis
For CRISPR-Cas9-mediated mutagenesis, 5x104 cells were seeded per well in a 24-well plate (Corning) and maintained at 37C in a
humidified 5%CO2 atmosphere overnight. Transfections using Lipofectamine 2000 was performed according to the manufacturer’s
instructions to transfect a pD1301-based plasmid (Horizon Discovery), which expresses Cas9, GFP and a small guide-RNA (sgRNA)
targeting the gene of interest. After incubating at 37C in a humidified 5%CO2 atmosphere for 48 hr, transfected cells were sorted by
flow cytometry using a BD Influx cell sorter and GFP-positive cells seeded 1 cell per well in 96-well plates (Corning) to generate clonal
cell lines which were then screened by immunoblotting to identify desired cell lines.
GFP tagging using CRISPR/Cas9
A biosensor line expressing GFP-tagged p53 was generated by co-transfecting HCT116 Flp-In T-RExTM cells with the pD1301-
AD:153663 plasmid (Horizon Discovery) containing a sgRNA targeting TP53 and a pBluescript-based plasmid containing an open
reading frame encodingGFP flanked by regions of TP53 generated by PCR amplification of genomic DNA isolated fromHCT116 cells
using Purelink Genomic DNA Mini kit (Invitrogen). To enrich for targeted clones, 10 days after transfection, cells were exposed to
Nutlin-3 for 24 hr to stabilize GFP-p53, green fluorescent cells isolated via sorting by flow cytometry, expanded into clones then
screened by immunoblotting to identify desired cell lines.
Targeted integration of p38a into HCT116 Flp-In cells
To reconstitute p38a function inMAPK14/, a p38a cDNA (Accession#: NM_139012) was amplified by RT-PCR using Superscript III
One Step RT-PCR Platinum Taq HiFi (Invitrogen) with RNA template extracted from HCT116 cells using RNeasy Plus Mini kit
(QIAGEN). This PCR product was cloned into pcDNA5/FRT/TO (Invitrogen) and transformed into XL1-Blue competent cells. Plasmid
DNA was extracted using QIAprep Spin Miniprep Kit (QIAGEN) and co-transfected with pOG44 into GFP-p53MAPK14/ HCT116
Flp-In T-RExTM cells. Following selection in 400 mg/ml hygromycin B (Sigma), colonies were pooled and expanded to create an
isogenic polyclonal cell line. Expression of p38a by the addition of tetracycline hydrochloride (1 mg/ml) was confirmed by
immunoblotting.
RNA interference
For RNAi-mediated inhibition, cells were plated in flat bottom, low evaporation 24-well plates (Corning) then transfected with a final
concentration of 66 nM of the desired siRNA using DharmaFECT 1 transfection reagent (Dharmacon) in Opti-MEM media
(Life-Technologies). Knock-down was confirmed by immunoblotting.e4 Cell Reports 25, 749–760.e1–e6, October 16, 2018
Cell cycle analysis
For DNA content analysis, cells were seeded in 6-well plates (Corning) then treated with small molecule inhibitors (AZ3146, 2 mM;
SB203580, 10 mM; DNA PKi, 10 mM) for 24 hr, fixed in ethanol overnight, treated with RNase A (50 mg/ml), stained with propidium
iodide (40 mg/ml) then analyzed on CyAn (DakoCytomation).
Immunoblotting
Proteins were extracted by boiling cell pellets in sample buffer (0.35 M Tris pH 6.8, 0.1 g/ml sodium dodecyl sulfate, 93 mg/ml dithio-
threitol, 30% glycerol, 50 mg/ml bromophenol blue), resolved by SDS-PAGE, then electroblotted onto Immobilon-P membranes.
Following blocking in 5% dried skimmed milk dissolved in TBST (50 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20), membranes
were incubated with primary antibodies overnight at 4C. Note, the following monoclonal and polyclonal antibodies were used: Anti-
mouse p53 (DO-1), anti-mouse p21 (F-5), anti-mouse Chk1 (G-4) (all from Santa Cruz Biotechnology); anti-mouse phospho-p38a
(T180/Y182) (R&D Systems), anti-mouse Hif1a (Clone 54) (BD Transduction Laboratories), anti-mouse p38a, anti-rabbit phospho-
MAPKAP-K2 (Thr334), anti-rabbit phospho-p53 (Ser 46), anti-rabbit p38 MAPK, anti-rabbit phospho-HSP27 (Ser82), anti-rabbit
phospho-MKK3/6 (Ser189/207), anti-rabbit phospho-p44/42 MAPK (ERK1/2), anti-rabbit phospho-SAPK/JNK (T183/Y185),
anti-rabbit phospho-Chk1 (Ser 345) (all Cell Signaling Technology); anti- rabbit ATM [Y170], anti-mouse phospho-ATM (S1981),
anti-rabbit DNA-PKcs, anti-rabbit phospho-DNA-PKcs (S2056) (All from Abcam); anti-mouse phospho-KAP1 (S824) (Bethyl Labora-
tories), anti-rabbit phospho-gamma H2AX (S139) (Novus Bio), anti-sheep Bub3 (A. Holland and S.S.-T., unpublished data),
anti-sheep Tao1 (Westhorpe et al., 2010). Membranes were then washed three times in TBST and incubated for at least 1 hr with
appropriate horseradish-peroxidase-conjugated secondary antibodies (Invitrogen). After washing in TBST, bound secondary
antibodies were detected using either EZ-ECLChemiluminescence Reagent (Geneflow) or LuminataTM ForteWestern HRPSubstrate
(Merck Millipore) and a Biospectrum 500 imaging system (UVP).
Cell fate profiling
Tomeasure proliferation, apoptosis induction, and to perform cell fate profiling, 13 105 cells were seeded per well in mclear 96 well
plates (Greiner Bio-One) and IncuCyte Kinetic Caspase-3/7 Apoptosis Assay Reagent (Essen BioScience) added. Shortly after
adding inhibitors, cells were then imaged using an IncuCyte ZOOM (Essen BioScience) equipped with a 20x objective and
maintained at 37C in a humidified 5% CO2 atmosphere. Phase contrast and fluorescence images (3-4 images per well) were
collected every 10-30 min and IncuCyte ZOOM software, used in real-time, measured confluence and fluorescence as a proxy
for proliferation and apoptosis, respectively. Apoptosis was quantitated bymeasuring green fluorescence object count in 3-4 images
per well, sampling at least 800 cells. Image sequences were then exported in MPEG-4 format and analyzed manually to generate cell
fate profiles. Timing data were imported into Prism 7 (GraphPad) for statistical analysis and presentation. Note that 0 hr on the fate
profiles represents when cells entered mitosis or when imaging started.
Metabolic profiling
To analyze glycolysis and oxidative phosphorylation, cells were analyzed in a Seahorse XFe96 Analyzer (Pike Winer and Wu, 2014).
1x103 cells were seeded per well in Agilent Seahorse 96-well XF Cell Culture microplates and incubated at 37C in a humidified 5%
CO2 atmosphere overnight. Seahorse XF cartridges were hydrated with Seahorse XF Calibrant and placed in a 0%CO2 incubator for
at least 6h. Prior to the assay, DMEM was replaced with XF Base Medium (37C, pH 7.35 ± 0.05) supplemented with 2 mM L-gluta-
mine only (glycolysis assay) or amixture of 2mM L-glutamine, 2mM sodium pyruvate and 10mMD-(+)-glucose (oxidative phosphor-
ylation assay). Compound injections for different stress tests were prepared according to the manufacturer’s instructions (Seahorse
XF Cell Mito Stress Test Kit and Seahorse XF Glycolysis Stress Test Kit) and added to the respective ports on the cartridge. Five
measurements were made for basal metabolism and three measurements were made for each compound injection. Results were
normalized for protein content in each well and assessed by Bradford assay (Bio-Rad). Note that values were derived from three
independent experiments.
Metaphase Spreads
For chromosome counting, cells were seeded in 6-well plates (Corning) and incubated at 37C in a humidified 5% CO2 atmosphere
for 24 hr. Cells were treated with 0.66 mM nocodazole for 6 hr, harvested and cell pellets incubated in hypotonic buffer for 20 min at
37Cbefore overnight fixation inmethanol:acetic acid (3:1). Samples were dropped onto glass slides and stainedwith Hoechst 33258
(Sigma). Images of individual metaphase spreads were taken on Zeiss Axiovert 200 with a 100x objective and chromosomes were
counted manually.
Colony Formation Assay
For colony formation assays, 500 cells were seeded per well in 6-well plates and incubated at 37C in a humidified 5% CO2 atmo-
sphere overnight. Cells were treated with the inhibitors and washed out after 24 hr of incubation. Cells were incubated for a further
13 days to allow colony development and finally fixed in 1% formaldehyde and stained with 0.05% (w/v) crystal violet solution. Col-
onies were counted using a GelCount (Oxford Optronix) and imaged using a ChemiDocTM Touch Imaging System (BioRad).Cell Reports 25, 749–760.e1–e6, October 16, 2018 e5
Single-cell whole-genome sequencing
Single G1 nuclei were isolated, sorted, and sequenced as described (Bakker et al., 2016; van den Bos et al., 2016) Briefly, cells were
incubated in a cytoplasmic lysis buffer and stained with propidium iodide (10 mg/mL) and Hoechst 33258 (10 mg/mL). Single G1 nuclei
were sorted in 96-well plates and stored in freezing medium at80C. Illumina-based library preparation was performed on a Bravo
Automated Liquid Handling Platform (Agilent Technologies). Samples were sequenced on an Illumina NextSeq 450 at ERIBA
(Illumina). Unprocessed sequencing reads were demultiplexed using library-specific barcodes and converted into fastq format using
standard Illumina software (bcl2fastq version 1.8.4). Demultiplexed reads were aligned to human reference genome GRCh38 using
Bowtie2 (version 2.2.4) (Langmead and Salzberg, 2012). Duplicate reads were marked and removed using BamUtil (version 1.0.3.).
Aligned sequencing reads were analyzed and curated using AneuFinder (version 1.4.0, Bakker et al., 2016) using 1Mb bins.
M-FISH
To prepare chromosome spreads, cells were seeded in 6-well plates (Corning) and incubated for 24 hrs, treated with 150 ng/ml
nocodazole for 4-8 hrs, then the entire population harvested by trypsinisation. Cell pellets were incubated for 25 mins at 37C in
0.8% sodium citrate hypotonic buffer followed by overnight fixation in freshly preparedmethanol:acetic acid (3:1). Samples in fixative
were dropped onto glass slides and air-dried overnight at room temperature and stained using Hoechst 33258 (Sigma). Images of
individual metaphase spreads were taken on Zeiss Axiovert 200 with a 100x objective and chromosomes manually counted. Slides
were then experimenter-blinded and hybridized with the M-FISH probe kit 24XCyte (Zeiss MetaSystems) following the manufacturer
instructions, then analyzed using an Olympus BX60 microscope for epifluorescence equipped with a Sensys CCD camera (Photo-
metrics, USA). Images were collected and analyzed using the Genus Cytovision software (Leica). A minimum of 25 metaphases were
karyotyped for each cell line/condition.
Time-lapse Microscopy
HCT116 Flp-In T-RExTM GFP-H2B cells were seeded in mclear 96 well plates (Greiner Bio-One) at 1x104 cells per well in FluoroBrite
DMEMmedia (Life Technologies) plus 1 mg/ml tetracycline hydrochloride and incubated at 37C in a humidified 5%CO2 atmosphere
for 24 hrs. GSK923295 and AZ3146 inhibitors were added at 100 nM and 0.5 mM respectively, and time-lapse microscopy was
performed on a manual microscope (Axiovert 200; Carl Zeiss, Inc.) equipped with an automated stage (PZ-2000; Applied Scientific
Instrumentation) and an environmental control chamber (Solent Scientific), which maintained the cells at 37C in a humidified stream
of 5% CO2. Imaging was performed using a 40x Plan NEOFLUAR objective. Shutters, filter wheels, and point visiting were driven by
MetaMorph software (MDS Analytical Technologies). Images were taken using an Evolve delta camera (Photometrics).
QUANTIFICATION AND STATISTICAL ANALYSIS
Prism 7 (GraphPad) was used for statistical analysis, where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: p > 0.05. Details of
statistical analyses are described in the Figure legends. Values on apoptosis and proliferation line graphs show the mean and SD or
SEM from three technical replicates. Lines on scatterplots show mean and interquartile ranges. Box-and-whisker plots show the
median, interquartile ranges, and the full range. To determine EACR and OCR, five measurements were made for basal metabolism
and three measurements were made for each compound injection (technical replicates). Results were normalized for protein content
in each well and assessed by Bradford assay (Bio-Rad). The values shown in Figure 5A show the mean and SEM from three
independent biological replicates and analyzed using a two-way Anova and Tukey multiple comparisons.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw unaligned single-cell sequencing reads reported in this paper is European Nucleotide Archive
(ENA): PRJEB27319.e6 Cell Reports 25, 749–760.e1–e6, October 16, 2018
